论文部分内容阅读
目的:评价自体DC-CIK细胞治疗晚期卵巢癌患者的临床疗效和安全性。方法:采集2011年8月至2016年1月解放军第81医院肿瘤生物治疗科收治的28例Ⅳ期卵巢癌患者的PBMC,经实验室体外诱导培养获得DC和CIK细胞。DC通过卵巢癌细胞(HO-8910)裂解物致敏后与CIK细胞回输至患者体内,观察DC-CIK细胞治疗前后患者临床疗效和安全性。结果:28例晚期卵巢癌患者经DC-CIK细胞免疫治疗后,ORR为7.1%(2/28),DCR为64.3%(18/28);12、36、50个月的累积生存率分别为有75%、53%和42%。经DC-CIK细胞治疗后患者外周血CD3~+CD8~+细胞比例显著升高[(23.35±7.52)%vs(29.49±8.16)%;t=-3.340,P<0.01],CD4~+/CD8~+比例显著下降[(1.61±0.84)%vs(1.21±0.74)%;t=2.785,P<0.05],CD3~+、CD3~+CD4~+、CD3~-CD56~+、CD4~+CD25~+细胞比例及CA125、CA199、TSGF水平均无显著变化(均P>0.05);患者治疗后均无明显不良反应。结论:DC-CIK细胞治疗可改善晚期卵巢癌患者免疫状态,提高其中远期生存率,患者无明显不良反应,安全可行。
Objective: To evaluate the clinical efficacy and safety of autologous DC-CIK cells in the treatment of advanced ovarian cancer. Methods: PBMC from 28 patients with stage Ⅳ ovarian cancer who were admitted to Department of Tumor Biotherapy, the 81st Hospital of Chinese People’s Liberation Army from August 2011 to January 2016 were collected and DCs and CIK cells were obtained by laboratory in vitro culture. DCs were transfused into CIK cells after being sensitized by lysate of ovarian cancer cells (HO-8910), and the clinical efficacy and safety of DC-CIK cells before and after treatment were observed. Results: The ORR rate was 7.1% (2/28) and the DCR was 64.3% (18/28) in 28 patients with advanced ovarian cancer after immunotherapy. The cumulative survival rates at 12, 36, and 50 months were There are 75%, 53% and 42%. The percentage of CD3 ~ + CD8 ~ + cells in peripheral blood of patients with DC-CIK was significantly higher than that of the patients with DC-CIK [(23.35 ± 7.52)% vs (29.49 ± 8.16)%, t = -3.340, CD8 ~ + ratio was significantly lower than that of control group ([(1.61 ± 0.84)% vs (1.21 ± 0.74)% vs t = 2.785, P <0.05] + CD25 ~ + cells and the levels of CA125, CA199 and TSGF had no significant change (all P> 0.05). There was no significant adverse reaction in the patients after treatment. Conclusion: DC-CIK cell therapy can improve the immune status of patients with advanced ovarian cancer and improve long-term survival rate of patients without obvious adverse reactions, safe and feasible.